Premium
Two cycles of cisplatin‐vindesine and radiotherapy for localized nonsmall cell carcinoma of the lung (stage III). Results of a prospective trial with 149 patients
Author(s) -
Tourani JeanMarc,
Timsit JeanFrançois,
Delaisement Corine,
Balzon JeanClaude,
Caubarrere Isabelle,
Darse Jacqueline,
Geraads Antoine,
Lebas FrançoisXavier,
Andrieu JeanMarie
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900401)65:7<1472::aid-cncr2820650704>3.0.co;2-o
Subject(s) - vindesine , medicine , radiation therapy , chemotherapy , complete response , stage (stratigraphy) , cisplatin , chemoradiotherapy , carcinoma , oncology , surgery , survival rate , vincristine , cyclophosphamide , paleontology , biology
One hundred forty‐nine patients with localized nonsmall cell carcinoma of the lung (Stage III A and B) were treated with two monthly cycles of initial chemotherapy that included vindesine‐cisplatin followed by 6000 cGy of thoracic irradiation. Patients with complete, partial, and minor response after initial chemotherapy were randomized into groups to receive either maintenance chemotherapy (four cycles) after radiotherapy or radiotherapy alone. The objective response rate was 24% after chemotherapy and 41% after combined chemoradiotherapy (complete response, 7.5%). The overall median survival was 9 months and the 2‐year survival was 14%. Survival was identical with or without maintenance chemotherapy. The 2‐year survival of patients with complete response was 75% compared with 9% for patients with partial or minor response. These results suggest that only the few patients (ten) who achieve complete response have a strong probability of survival. It is therefore essential to search for other therapeutic modalities that result in an increase of the complete response rate.